The U.S. Food and Drug Administration on Wednesday approved the first drug to treat a "full range" of narcolepsy type 1 symptoms in adults.

Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with Lilly and Alkermes close behind.

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1